Welcome to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
NB: We use cookies to help personalise your web experience and comply with Irish healthcare law. Whatever your choice, you are agreeing to our use of cookies. Please close this browser tab if you don't want to proceed.
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

June 30, 2016


Company: Athlone Laboratories Ltd.
Legal category: Prescription. GMS. Sport permitted.
Active ingredient: Trimethoprim 200mg
Description: Flat, white, bevelled-edge tablets embossed TR 200.
Presentation: 100, €12.20.
Indications: Treatment of infections caused by susceptible organisms including most gram-positive and gram-negative aerobic organisms (H. influenza, S. pneumoniae, K. pneumoniae, S. aureus, E. coli, S. faecalis, Enterobacter and Proteus species). Exceptions include anaerobic bacteria, M. tuberculosis, N. gonorrhoeae, P. aeruginosa, T. pallidum, Nocardia, Mycobacteria and Neisseria species. Prophylaxis of recurrent urinary tract infections.

Pharmacology: Antibiotic. Trimethoprim affects the nucleoprotein metabolism of the cells similarly to pyrimethamine by interference with the folic-folinic acid systems. Its effects are considerably greater on the cells of micro-organisms than on mammalian cells. Sulphonamides act on the same biological pathway at a different point and the effects of sulphonamides and trimethoprim are synergic.
Dosage: Adult: UTI and all other susceptible infections, 200mg twice daily. Long term prophylaxis of recurrent UTI, 100mg at night before bedtime. Elderly: Mild to moderate renal insufficiency, monitor serial levels of Trimoptin on days 2 to 4 and adjust dosage according to creatinine clearance (cc ≥25ml/min, reduce maintenance dose after 2 days; 10ml/min≤ cc ≤25ml/min, half dose). Children: Four months to 12 years, not recommended. Over 12 years, as per adults.
Contraindications: Infants under 4 months. Severe hepatic insufficiency. Severe renal insufficiency. Megaloblastic anaemia and other blood dyscrasias. Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Pregnancy, lactation.
Special precautions: Marked renal impairment: Avoid accumulation and resulting adverse hepatological effect. Regular haematological tests in long term treatment and patients predisposed to folate deficiency. Take particular care in the haematological monitoring of children on long term therapy. Prolonged use may result in the development of super infection.
Drug interactions: Warfarin. In elderly patients concurrently receiving certain diuretics (primarily thiazides) an increased incidence of thrombocytopenia with purpura may occur. May increase serum levels of digoxin, phenytoin and procainamide. Concomitant cyclosporin may increase nephrotoxicity risk. May interfere with diagnostic tests including serum methotrexate assay where dihydrofolate reductase is used and the Jaffe reaction for creatinine.
Adverse drug reactions: Uncommon.
Full prescribing information and references available from Athlone Laboratories Ltd, Ballymurray, Co. Roscommon. Telephone: (090) 6661109. Fax: (090) 6661921. E-mail: info@athlone-laboratories.com